全文获取类型
收费全文 | 3538篇 |
免费 | 309篇 |
国内免费 | 36篇 |
专业分类
耳鼻咽喉 | 47篇 |
儿科学 | 176篇 |
妇产科学 | 49篇 |
基础医学 | 431篇 |
口腔科学 | 9篇 |
临床医学 | 359篇 |
内科学 | 1015篇 |
皮肤病学 | 33篇 |
神经病学 | 267篇 |
特种医学 | 55篇 |
外科学 | 545篇 |
综合类 | 127篇 |
一般理论 | 2篇 |
预防医学 | 455篇 |
眼科学 | 51篇 |
药学 | 117篇 |
中国医学 | 12篇 |
肿瘤学 | 133篇 |
出版年
2023年 | 36篇 |
2022年 | 29篇 |
2021年 | 66篇 |
2020年 | 51篇 |
2019年 | 20篇 |
2018年 | 72篇 |
2017年 | 55篇 |
2016年 | 63篇 |
2015年 | 87篇 |
2014年 | 70篇 |
2013年 | 110篇 |
2012年 | 291篇 |
2011年 | 250篇 |
2010年 | 113篇 |
2009年 | 96篇 |
2008年 | 216篇 |
2007年 | 270篇 |
2006年 | 232篇 |
2005年 | 286篇 |
2004年 | 233篇 |
2003年 | 232篇 |
2002年 | 202篇 |
2001年 | 126篇 |
2000年 | 57篇 |
1999年 | 39篇 |
1998年 | 23篇 |
1997年 | 18篇 |
1996年 | 22篇 |
1994年 | 21篇 |
1993年 | 20篇 |
1992年 | 51篇 |
1991年 | 29篇 |
1990年 | 33篇 |
1989年 | 41篇 |
1988年 | 32篇 |
1987年 | 25篇 |
1986年 | 27篇 |
1985年 | 15篇 |
1984年 | 11篇 |
1983年 | 16篇 |
1982年 | 21篇 |
1981年 | 12篇 |
1980年 | 13篇 |
1979年 | 25篇 |
1978年 | 18篇 |
1977年 | 19篇 |
1976年 | 14篇 |
1975年 | 11篇 |
1974年 | 10篇 |
1973年 | 13篇 |
排序方式: 共有3883条查询结果,搜索用时 31 毫秒
81.
Ko DT Donovan LR Huynh T Rinfret S So DY Love MP Galbraith D Tu JV;Canadian Cardiovascular Outcomes Research Team 《The Canadian journal of cardiology》2008,24(11):839-843
BACKGROUND:
Historically, access to primary percutaneous coronary intervention (PCI) for the treatment of patients with ST segment elevation myocardial infarction (STEMI) has been limited in Canada. Recent studies have identified innovative strategies to improve timely access and reduce reperfusion time. Accordingly, the contemporary use of primary PCI treatment in Canada was ascertained.METHODS:
A cross-sectional survey of all 38 Canadian hospitals that were capable of performing PCI procedures was conducted from June 2007 to November 2007. The survey focused on the practice of primary PCI for patients with STEMI and whether the hospitals had implemented internal strategies to reduce ‘door-to-balloon’ times. Analyses were performed at the level of geographical regions.RESULTS:
Overall, 71% of PCI hospitals (27 of 38) provided around-the-clock primary PCI for patients with STEMI, but the proportion of PCI hospitals offering this service varied widely, from 33% to 100% across regions. All Canadian PCI hospitals provided around-the-clock rescue PCI treatment to STEMI patients who had failed fibrinolytic therapy. In terms of strategies that are associated with reduced reperfusion time, it was observed that only 42% of PCI hospitals (16 of 38) provided feedback on door-to-balloon time to the emergency department and to the cardiac catheterization laboratories within one week of the primary PCI procedure. Overall, 24% of the hospitals had not adopted any of the four identified strategies to improve door-to-balloon time.CONCLUSION:
Although the majority of Canadian hospitals with PCI capability provide around-the-clock primary PCI for patients with STEMI, significant variations in this practice exist across the country. Canadian PCI hospitals have not consistently adopted strategies that are associated with improved door-to-balloon time. 相似文献82.
Diaz MA Gonzalez-Vicent M Gonzalez ME Verdeguer A Martinez A Perez-Hurtado M Badell I de la Rubia J Bargay J de Arriba F Diez JL Caballero D Madero L Brunet S;Spanish Working Party for Blood Marrow Transplantation in Children;Spanish Group for Allogeneic Peripheral Blood Transplantation 《Bone marrow transplantation》2005,36(9):781-785
We analyzed the clinical outcome in 90 children undergoing allogeneic PBSC transplantation from HLA-identical relative for leukemia. GvHD prophylaxis was CsA+ methotrexate in 50 and CsA+/-steroids in 40. Median CD34+ cells infused were 6 x 10(6)/kg (range, 1.4-32). Median follow-up was 60 months (range, 6-115). CI of transplant-related mortality (TRM) was 18.4+/-4%. On multivariate analysis, high Lansky score (>80) at transplantation was associated with lower TRM (HR, 0.9; P<0.0002). Relapse incidence (RI) was 33.6+/-6%. On multivariate analysis, high Lansky score at transplantation and cGvHD were associated with lower RI (HR, 0.04; P<0.0005 and HR, 0.23; P<0.03, respectively). Disease-free survival (DFS) was 57.8+/-5%. Disease status at transplantation (HR, 0.33; P<0.02), steroid treatment at day +90 (HR, 5.61; P<0.005) and cGvHD (HR, 0.23; P<0.005) had a significant impact on DFS in multivariate analysis. CI of cGvHD was 63.7+/-7%. Patients with cGvHD had better DFS (65+/-5%) because of lower RI (15.7+/-6%) and similar TRM (27.4+/-4%). These data suggest acceptable long-term outcomes after allogeneic PBSC transplantation in children despite the high incidence of cGvHD. These patients had a lower risk of relapse and a better DFS. 相似文献
83.
Arastéh K Clumeck N Pozniak A Lazzarin A De Meyer S Muller H Peeters M Rinehart A Lefebvre E;TMC-C Study Team 《AIDS (London, England)》2005,19(9):943-947
OBJECTIVE: To evaluate antiviral activity, tolerability, and safety of the protease inhibitor (PI) TMC114 boosted with low-dose ritonavir (RTV). DESIGN: A randomized, open-label, controlled, phase IIA clinical trial in 15 sites in Europe with 50 HIV-1-infected patients who had taken multiple PIs. METHODS: At entry, PIs in non-suppressive regimens were replaced with TMC114/RTV (300/100 or 600/100 mg twice daily, or 900/100 mg once daily) or left unchanged for 14 days. The time-averaged difference (DAVG) in HIV-1 RNA from baseline, change in HIV-1 RNA from baseline, proportions achieving plasma HIV-1 RNA < 400 copies/ml and > or = 0.5 and > or = 1.0 log10 copies/ml reductions in HIV-1 RNA, and safety were assessed. RESULTS: DAVG responses in all TMC114/RTV groups (range, -0.56 to -0.81 log10 copies/ml) were significantly greater (P < 0.001) than in the controls (-0.03 log10 copies/ml). Median change at day 14 was -1.38 and +0.02 log10 copies/ml for all TMC114/RTV groups and the control group, respectively. A reduction of > or = 0.5 and > or = 1.0 log10 copies/ml was attained by 97% and 76% of patients, respectively, in all TMC114/RTV groups and by 25% and 17%, respectively, in the control group. HIV-1 RNA < 400 copies/ml at any time during treatment was achieved by 40% in the TMC114/RTV groups and 8% in the control group. Most common reported adverse events were gastrointestinal and central nervous system disorders (mild to moderate severity). No dose relationship was observed. Biochemical, haematological and electrocardiographic parameters showed no significant changes. CONCLUSIONS: TMC114/RTV demonstrated a potent antiretroviral effect over 14 days in multiple-PI-experienced patients and was generally well tolerated. 相似文献
84.
L J Deftos H G Bone J G Parthemore 《The Journal of clinical endocrinology and metabolism》1980,51(4):857-862
A series of 59 thyroidal C cell neoplasms was studied by immunoperoxidase histology. These neoplasms included human medullary thyroid carcinoma and C cell hyperplasia and rat medullary thyroid carcinoma. In addition to calcitonin, the tumors were studied by immunohistology for the presence of beta-endorphin, ACTH, and somatostain. All but one of the neoplasms were positive for calcitonin, 25 of 31 were positive for beta-endorphin, 12 of 18 were positive for ACTH, and 9 of 19 were positive for somatostatin immunoreactivity. Many tissues contained all 4 peptides, and in some sections these peptide immunoreactivities seemed to be present in the same cells. These studies suggest that there is a relationship in these tumors among the 4 peptides studied, but the basis of this relationship is not clear. 相似文献
85.
A J Bone R W Gumpert S L Howell J Sheldon M Tellez-Yudilevich M Tyhurst P G Whittaker F Zaheer 《The Journal of endocrinology》1977,74(2):273-280
The regulation of insulin biosynthesis, and insulin and glucagon secretion have been investigated in a human islet cell adenoma, by incubation of tumour fragments. Both biosynthesis and secretion of insulin were strongly stimulated by incubation of islet tumour cells in the presence of increasing glucose concentrations in the range 2-8 mmol/1. However, 20 mM-glucose or 20 mM-glucose plus isobutyl methylxanthine (IBMX), both of which provide potent secretagogues for normal B cells, failed to stimulate proinsulin biosynthesis and secretion from the tumour cells. Overall rates of secretion, expressed as a proportion of total insulin content, were up to 20-fold higher than those expected for normal pancreatic tissue. Glucagon secretion from the tumour was stimulated by low glucose concentrations; normal A cells also respond in this way under these conditions. However, no stimulation of glucagon secretion occurred in the presence of IBMX. There was therefore a major alteration in the regulation both of insulin and glucagon secretion, in that release of neither hormone was stimulated by cyclic AMP. Ultrastructural examination showed the tumour to be rather heterogeneous. A and B cells with normal storage granule content and structure were seen, as well as a rather larger number of B cells containing some granules of atypical appearance. The insulin content of the tumour (13 i.u./g wet wt) was consistent with 6-8% of the tumour cells being B cells. 相似文献
86.
Arat M Arpaci F Ertem M Gürman G;Turkish Transplant Registry 《Bone marrow transplantation》2008,42(Z1):S142-S145
SCT is a curative approach using chemo-, radio- and immunotherapy for malignant and non-malignant hematological disorders. The European Group for Blood and Marrow Transplantation (EBMT) has been collecting yearly data on a survey basis since 1990. The variables within the survey are limited to detailed indications, number of patients, transplant type, stem cell source, type of conditioning regimen and donor type. The transplant rates in certain indications, patterns of stem cell source selection and donor availability and alternative donor use were analyzed in detail. The Turkish transplant registry data within EBMT-European Activity Survey (EBMT-EAS) were delivered by the EBMT Activity Survey Office. We compared the national data with the international EBMT-EAS data pool. 相似文献
87.
88.
Cummins M Cwynarski K Marktel S Dazzi F Cavenagh J Clark RE Holyoake TL Milligan D Parker A Russell NH Marks DI;Clinical Trials Committee British Society of Blood & Marrow Transplantation 《Bone marrow transplantation》2005,36(12):1065-1069
Donor lymphocyte infusion (DLI) can restore remission in a high percentage of patients with chronic myeloid leukaemia (CML) who relapse after allogeneic stem cell transplant (SCT). Subsequent relapses after a DLI-induced remission do occur and the optimal management of these patients is not defined. A retrospective study of the practice of UK transplant centres was conducted. In all, 13 patients from seven centres were identified: all were treated for relapse post allogeneic SCT with DLI and achieved either a complete cytogenetic (n=5) or molecular (n=8) remission. All patients subsequently had a second relapse, at molecular (n=7), cytogenetic (n=4) and haematological (n=2) levels. Further DLI was used in the treatment of 11 patients, imatinib mesylate in three and chemotherapy in two. The two patients with haematological relapse died of blastic disease. The remaining 11 patients achieved either a complete cytogenetic (n=2) or molecular (n=9) remission. Nine patients remain in molecular remission at a median follow-up of 29 months, seven of whom had received DLI alone as treatment for second relapse, one DLI plus imatinib and one imatinib alone. Toxicity following DLI for second relapse was low. Longer follow-up will be required to see if these second DLI-induced remissions will be durable. 相似文献
89.
Hypoxanthine uptake and release by equilibrative nucleoside transporter 2 (ENT2) of rat microvascular endothelial cells 总被引:1,自引:0,他引:1
The cardioprotective actions of adenosine are terminated by its uptake into endothelial cells with subsequent metabolism through hypoxanthine to uric acid. This process involves xanthine oxidase-mediated generation of reactive oxygen species (ROS), which have been implicated in the vascular dysfunction observed in ischemia-reperfusion injury. The equilibrative nucleoside transporter, ENT2, mediates the transfer of hypoxanthine into cells. We hypothesize that ENT2 also mediates the cellular release of hypoxanthine, which would limit the amount of intracellular hypoxanthine available for xanthine oxidase-mediated ROS production. Rat microvascular endothelial cells (MVECs) were isolated from skeletal muscle by lectin-affinity purification. The transport of [(3)H]hypoxanthine was assessed using an oil-stop method, and hypoxanthine metabolites were identified by thin-layer chromatography. MVECs accumulated hypoxanthine with a K(m) of 300 microM and a V(max) of 2.8 pmol microl(-1) s(-1). ATP-depleted cells loaded with [(3)H]hypoxanthine released the radiolabel with kinetics similar to that obtained for [(3)H]hypoxanthine influx. The uptake and release of [(3)H]hypoxanthine were both blocked by ENT2 inhibitors with similar order of potency. Thus, ENT2 mediates both the influx and efflux of hypoxanthine. Inhibition of ENT2 in MVECs might be expected to increase the amount of intracellular hypoxanthine available for metabolism by xanthine oxidase and enhance the intracellular production of ROS. 相似文献
90.